Potential Role of Monocyte Chemoattractant Protein-1 in Monitoring Disease Progression and Response to Treatment in Overactive Bladder Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To compare urinary levels of monocyte chemoattractant protein-1 (MCP-1), an inflammatory cytokine, in healthy controls and overactive bladder (OAB) patients, to correlate changes in urinary MCP-1 with OAB treatment response and symptom severity, and to study the diagnostic potential of MCP-1 for OAB, as well as the efficacy of MCP-1 as a potential biomarker for different phenotypes of OAB. Methods: We used enzyme-linked immunosorbent assay to measure normalized urinary MCP-1 levels in 56 individuals (43 OAB patients and 13 controls). We assessed the OAB patients at 3 visits with 2 validated symptom severity questionnaires (OAB-V8 and Patient Perception of Bladder Condition). Results: The mean pretreatment urinary MCP-1 level at visit 1 (229.2-pg/mg creatinine) was significantly greater than the MCP-1 levels at visit 3 in both the treatment (107.0-pg/mg creatinine) (P<0.001) and control (52.35-pg/mg creatinine) groups (P<0.001). Average OAB symptom severity decreased significantly from visit 1 (baseline) to visits 2 (4 weeks) and 3 (12–14 weeks) and was significantly correlated with urinary MCP-1 levels. Urinary MCP-1 levels dropped significantly (P=0.002) posttreatment in patients whose symptom severity improved by >30%, whereas nonresponders displayed no significant MCP-1 decrease (P=0.164). The receiver operating characteristic analysis of the OAB visit 1 and control groups produced an area under the curve of 0.891. We found no significant differences in sex, race, or age between the OAB and control groups. Conclusions: MCP-1 levels differed significantly between the control and OAB groups and were closely correlated with symptom severity and treatment response. The good diagnostic accuracy of MCP-1 for OAB suggests the potential usage of MCP-1 for OAB diagnosis. The varying response of urinary MCP-1 levels to treatment may indicate at least 2 potential phenotypes of OAB. MCP-1, in combination with other biomarkers and symptom severity questionnaires, could potentially aid in developing a patient-centered OAB treatment approach.
Abstract
Purpose: To compare urinary levels of monocyte chemoattractant protein-1 (MCP-1), an inflammatory cytokine, in healthy controls and overactive bladder (OAB) patients, to correlate changes in urinary MCP-1 with OAB treatment response and symptom severity, and to study the diagnostic potential of MCP-1 for OAB, as well as the efficacy of MCP-1 as a potential biomarker for different phenotypes of OAB. Methods: We used enzyme-linked immunosorbent assay to measure normalized urinary MCP-1 levels in 56 individuals (43 OAB patients and 13 controls). We assessed the OAB patients at 3 visits with 2 validated symptom severity questionnaires (OAB-V8 and Patient Perception of Bladder Condition). Results: The mean pretreatment urinary MCP-1 level at visit 1 (229.2-pg/mg creatinine) was significantly greater than the MCP-1 levels at visit 3 in both the treatment (107.0-pg/mg creatinine) (P<0.001) and control (52.35-pg/mg creatinine) groups (P<0.001). Average OAB symptom severity decreased significantly from visit 1 (baseline) to visits 2 (4 weeks) and 3 (12–14 weeks) and was significantly correlated with urinary MCP-1 levels. Urinary MCP-1 levels dropped significantly (P=0.002) posttreatment in patients whose symptom severity improved by >30%, whereas nonresponders displayed no significant MCP-1 decrease (P=0.164). The receiver operating characteristic analysis of the OAB visit 1 and control groups produced an area under the curve of 0.891. We found no significant differences in sex, race, or age between the OAB and control groups. Conclusions: MCP-1 levels differed significantly between the control and OAB groups and were closely correlated with symptom severity and treatment response. The good diagnostic accuracy of MCP-1 for OAB suggests the potential usage of MCP-1 for OAB diagnosis. The varying response of urinary MCP-1 levels to treatment may indicate at least 2 potential phenotypes of OAB. MCP-1, in combination with other biomarkers and symptom severity questionnaires, could potentially aid in developing a patient-centered OAB treatment approach.
참고문헌 (25)
- Abrams P, "The standardization of terminology of lower urinary tract function : report from the Standardization Sub-committee of the International Continence Society", Am J Obstet Gynecol, 187, pp.116~126 (2002)
- Antunes-Lopes T, "Urinary neurotrophic factors in healthy individuals and patients with overactive bladder", J Urol, 189, pp.359~365 (2013)
- Bhide AA, "Biomarkers in overactive bladder", Int Urogynecol J, 24, pp.1065~1072 (2013)
- Kim JC, "Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder", J urol, 175, pp.1773~1776 (2006)
- Liu HT, "Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy", PloS One, 8, pp.e76706~ (2013)
- Wang LW, "Urinary brain-derived neurotrophic factor : a potential biomarker for objective diagnosis of overactive bladder", Int Urol Nephrol, 46, pp.341~347 (2014)
- Tyagi P, "Urine cytokines suggest an inflammatory response in the overactive bladder : a pilot study", Int Urol Nephrol, 42, pp.629~635 (2010)
- Ghoniem G, "Differential profile analysis of urinary cytokines in patients with overactive bladder", Int Urogynecol J, 22, pp.953~961 (2011)
- Deshmane SL, "Monocyte chemoattractant protein-1(MCP-1) : an overview", J Interferon Cytokine Res, 29, pp.313~326 (2009)
- Naruse K, "A YAC contig of the human CC chemokine genes clustered on chromosome 17q11.2", Genomics, 34, pp.236~240 (1996)
- Chocran BH, "Molecular cloning of gene sequences regulated by platelet-derived growth factor", Cell, 33, pp.939~947 (1983)
- Feuser K, "Human intestinal mast cells are a potent source of multiple chemokines", Cytokine, 58, pp.178~185 (2012)
- Beall CJ, "Site-directed mutagenesis of monocyte chemoattractant protein-1 identifies two regions of the polypeptide essential for biological activity", Biochem J, 313, pp.633~640 (1996)
- Jiang Y, "Posttranslational modification of a monocyte-specific chemoattractant synthesized by glioma, osteosarcoma, and vascular smooth muscle cells", J Biol Chem, 265, pp.18318~18321 (1990)
- Desireddi NV, "Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1α as possible biomarkers for the chronic pelvic pain syndrome", J Urol, 179, pp.1857~1862 (2008)
- Tanaka ST, "Recruitment of bone marrow derived cells to the bladder after bladder outlet obstruction", J Urol, 182, pp.1769~1774 (2009)
- Farhan B, "Characterizations of urinary monocyte chemoattractant protein 1 : Potential biomarker for patients with overactive bladder", Arab J Urol, 17, pp.58~60 (2019)
- Lightner DJ, "Diagnosis and treatment of overactive bladder(non-neurogenic)in adults : AUA", SUFU guideline amendment 2019, 2019, pp.202, 558~563
- Geppetti P, "The concept of neurogenic inflammation", BJU Int, 101, pp.2~6 (2008)
- Ziraldo C, "Central role for MCP-1", CCL2 in injury-induced inflammation revealed by in vitro, in silico, and clinical studies, 2013, pp.8, e79804~
- Yoshimura N, "Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation", J Neurosci, 19, pp.4644~4653 (1999)
- Stephan M, "Urinary concentration and tissue messenger RNA expression of monocyte chemoattractant protein-1 as an indicator of the degree of hydronephrotic atrophy in partial ureteral obstruction", J Urol, 167, pp.1497~1502 (2002)
- Firat E, "Exploring biomarkers in the overactive bladder : alterations in miRNA levels of a panel of genes in patients with OAB", Neurourol Urodyn, 38, pp.1571~1578 (2019)
- Siddiqui NY, "Biomarkers implicated in lower urinary tract symptoms", J Urol, 202, pp.880~889 (2019)
- Firouzmand S, "New participant stratification and combination of urinary biomarkers and confounders could improve diagnostic accuracy for overactive bladder", Sci Rep, 10, pp.3085~ (2020)